JONATHAN TRENT
Estados Unidos
Professor of Medicine
Associate Director for Clinical Research
Director, Sarcoma Medical Research Program
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Miami, FL
Jonathan C. Trent, MD, PhD, focuses his clinical, educational, and research efforts on GIST,
chondrosarcoma, and other sarcomas. His interests include the clinical and translational research of
sarcomas, the direct care of patients with sarcoma, and education about sarcoma and patient-oriented
research. As Associate Director for Clinical Research, his goal is to help Sylvester faculty develop clinical
trials that provide clinically effective and scientifically exciting therapy to patients with cancer. The
major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of
imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work
involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue,
cell lines, and archival tissue.
Estados Unidos
Professor of Medicine
Associate Director for Clinical Research
Director, Sarcoma Medical Research Program
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Miami, FL
Jonathan C. Trent, MD, PhD, focuses his clinical, educational, and research efforts on GIST,
chondrosarcoma, and other sarcomas. His interests include the clinical and translational research of
sarcomas, the direct care of patients with sarcoma, and education about sarcoma and patient-oriented
research. As Associate Director for Clinical Research, his goal is to help Sylvester faculty develop clinical
trials that provide clinically effective and scientifically exciting therapy to patients with cancer. The
major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of
imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work
involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue,
cell lines, and archival tissue.